Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience
Classical Hodgkin lymphoma (cHL) is considered a curable disease; however, in
approximately one-third of the responding patients, the disease relapses following …
approximately one-third of the responding patients, the disease relapses following …
Brentuximab vedotin for relapsed or refractory Hodgkin lymphoma: experience in Turkey
Current treatment modalities can cure up to 70–80% of patients with classical Hodgkin
lymphoma. Approximately, 20–30% of patients require further treatment options …
lymphoma. Approximately, 20–30% of patients require further treatment options …
Real-world experience of PD-1 inhibitors for relapsed and refractory Hodgkin lymphoma: A multicenter retrospective analysis of patients in China
W Yu, M Geng, J Hao, Z Yan, JQ Mi - Acta Haematologica, 2023 - karger.com
Introduction: Despite the promising clinical trial data regarding programmed death 1 (PD-1)
inhibitors in relapsed/refractory classical Hodgkin lymphoma (R/R cHL), there remains a …
inhibitors in relapsed/refractory classical Hodgkin lymphoma (R/R cHL), there remains a …
A targeted salvage therapy with Brentuximab vedotin in heavily treated refractory or relapsed pediatric Hodgkin lymphoma patients before and after stem cell …
N Taçyıldız, HG Tanyıldız, E Ünal… - The Turkish Journal …, 2019 - turkjpediatr.org
Taçyıldız N, Tanyıldız HG, Ünal E, Dinçaslan H, Asarcıklı F, Adaklı Aksoy B, Vatansever G,
Yavuz G. A targeted salvage therapy with Brentuximab vedotin in heavily treated refractory …
Yavuz G. A targeted salvage therapy with Brentuximab vedotin in heavily treated refractory …